Side-by-side financials for ALT and JNJ. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALT | JNJ |
|---|---|---|
| Market cap | - | $579.39 B |
| US-listed rank | - | #20 |
| Revenue (latest FY) | $41.00K | $94.19B |
| Net income (latest FY) | -$88.09M | $26.80B |
| Net margin | -214861.0% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 997 | 984 |
In their latest fiscal years, Altimmune, Inc. reported $41.00K in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Altimmune, Inc. and JOHNSON & JOHNSON, or browse the full rankings.